Promising new treatments for pancreatic cancer and ALS
Summary
This episode highlights two major medical breakthroughs. Dr. Zev Weinberg discusses sotorasib, a new drug that significantly improves survival for advanced pancreatic cancer by targeting the KRAS gene. Later, New York Times reporter Pam Bellick covers tofersen, the first disease-modifying therapy for a rare genetic form of ALS, which has helped some patients stabilize or improve their symptoms.
Topics discussed
Sponsor message from Progressive Insurance
Introduction: New pancreatic cancer drug Darexonrasib
Clinical trial results: Doubling survival rates
Historical significance of the breakthrough
Targeting the KRAS oncogene in various cancers
Effectiveness in lung and colon cancer
FDA review timeline and emotional impact on trials
Future treatment lines and early intervention
Science Friday fundraising and New York Community Trust
ALS drug Tofersen for SOD1 genetic mutation
How Tofersen works and patient improvements
Patient story: Amanda Sifford's recovery
Drug availability, cost, and trials for non-SOD1 ALS
Side effects and spinal inflammation management
Preventative trials for asymptomatic carriers
Credits and listener contact information
Listen ad-free on Castria